Article | May 2, 2018

Rise In Targeted Therapies Drives Need For Flexible, Small-Volume Manufacturing

Source: Patheon, part of Thermo Fisher Scientific
Vials With Syringe

Biologics have experienced steady double-digit growth over the last 15 years and now comprise slightly more than a quarter of all New Molecular Entity (NME) FDA approvals. Similarly, EvaluatePharma’s 2017 report on orphan drugs projects that by 2020, six of the 10 best-selling global drug therapies will be biologic sterile injectable drugs. Precision medicine is also on the rise, with the FDA approving a record number of precision drugs in 2017. The rise in these targeted therapies means big changes for drug development and manufacturing companies.

Patheon, part of Thermo Fisher Scientific